Squamous cell carcinoma future and investigational treatment strategies: Difference between revisions
(Created page with "{{Squamous cell carcinoma}} {{CMG}}; '''Associate Editor(s)-in-Chief:''' Aditya Govindavarjhulla, M.B.B.S. [mailto:agovi@perfuse.org],[[User:R...") |
|||
| Line 3: | Line 3: | ||
== Future and Investigational treatment strategies == | == Future and Investigational treatment strategies == | ||
In 2007, Australian biopharmaceutical company | In 2007, the Australian biopharmaceutical company, Clinuvels Pharmaceuticals Limited began [[clinical trials]] with a [[melanocyte-stimulating hormone]] called [[melanotan]] (known by the [[International Nonproprietary Name]] ''afamelanotide'', formerly CUV1647)<ref name="Clinuvel-INN">{{Cite web|url=http://www.clinuvel.com/resources/pdf/asx_announcements/2008/20080617WHOGenericName.pdf|title=World Health Organisation assigns CUV1647 generic name|accessdate=2008-06-17|publisher=Clinuvel|year=2008|format=[[Portable Document Format|PDF]]}}</ref> to provide [[photoprotection]] for organ transplant patients against squamous cell carcinoma of the skin and [[actinic keratosis]].<ref name="Clinuvel">[http://www.clinuvel.com/en/faqs/ Clinuvel » Investors » FAQs<!-- Bot generated title -->]</ref><ref name="PharmaAsia">[http://www.pharmaasia.com/article-6618-clinuvelsdrugbeginsglobalphaseiiskincancertrials-Asia.html PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials]</ref> | ||
[[Cetuximab]] a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin | [[Cetuximab]] a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin as suggested by case reports. | ||
The use of natural agents in the treatment of cancer is gaining popularity. For oral squamous cell carcinoma , use of curcumin microemulsions is under consideration. New modalities, such as the use of ultrasound mediated delivery of these microemulsions are also being investigated. <ref name="pmid3289448">{{cite journal|author=Lenaz G, Fato R, Baracca A, Solaini G, Parenti Castelli G, Rabbi A |title=Dynamics of biological membranes |journal=Ann. Ist. Super. Sanita |volume=24 |issue=1 |pages=9–21 |year=1988 |pmid=3289448 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 21:05, 22 July 2012
|
Squamous cell carcinoma of the skin Microchapters |
|
Differentiating Squamous cell carcinoma of the skin from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Squamous cell carcinoma future and investigational treatment strategies On the Web |
|
American Roentgen Ray Society Images of Squamous cell carcinoma future and investigational treatment strategies |
|
FDA on Squamous cell carcinoma future and investigational treatment strategies |
|
CDC on Squamous cell carcinoma future and investigational treatment strategies |
|
Squamous cell carcinoma future and investigational treatment strategies in the news |
|
Blogs on Squamous cell carcinoma future and investigational treatment strategies |
|
Directions to Hospitals Treating Squamous cell carcinoma of the skin |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2],Raviteja Guddeti, M.B.B.S. [3]
Future and Investigational treatment strategies
In 2007, the Australian biopharmaceutical company, Clinuvels Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[1] to provide photoprotection for organ transplant patients against squamous cell carcinoma of the skin and actinic keratosis.[2][3]
Cetuximab a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin as suggested by case reports.
The use of natural agents in the treatment of cancer is gaining popularity. For oral squamous cell carcinoma , use of curcumin microemulsions is under consideration. New modalities, such as the use of ultrasound mediated delivery of these microemulsions are also being investigated. [4]
References
- ↑ "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel. 2008. Retrieved 2008-06-17.
- ↑ Clinuvel » Investors » FAQs
- ↑ PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials
- ↑ Lenaz G, Fato R, Baracca A, Solaini G, Parenti Castelli G, Rabbi A (1988). "Dynamics of biological membranes". Ann. Ist. Super. Sanita. 24 (1): 9–21. PMID 3289448.
de:Plattenepithelkarzinom
he:קרצינומת תאי קשקש
nl:Plaveiselcelcarcinoom